ST. PAUL, Minn., Dec. 7 /PRNewswire-FirstCall/ -- Hypertension Diagnostics Inc. (BULLETIN BOARD: HDII) has hired four people in an aggressive move to expand the market for its CVProfilor(R), a cardiovascular screening device that determines if patients have potential underlying vascular disease -- a precursor to heart attacks and strokes.
George Welisevich was appointed Customer Service Manager and is responsible for increasing utilization of the CVProfilor with the existing base of physicians. Welisevich brings over 21 years of experience with industry leader Smiths Medical to HDI. His expertise in the diabetic field will be used to expand the marketing of the CVProfilor to endocrinologists.
Garry John Ince, Account Manager for New York and New Jersey, will focus on bringing new physician customers on board in that market. He was the highest grossing sales representative at CR Bard in New York in 2003 and has over ten years experience working with cardiologists and internists in the Tri-State area.
Carl Weissberg, Account Manager for Southern California, is responsible for market development in Orange County and Southern California. His 20-year pharmaceutical and medical device sales career includes positions at KOS and AstraZeneca PLC. He will leverage his extensive network of internists and endocrinologists to expand the market for the CVProfilor in this region.
Sarah Doyle, Customer Service and Sales Coordinator, will assist with customer training and support. Previously she was a Training Coordinator for the Diabetes Division at Smiths Medical.
"Consumer interest in the prevention of heart disease has peaked in the wake of Bill Clinton's heart surgery and the CVProfilor has gained increased acceptance in the field of preventative cardiovascular health," said Mark Schwartz, Chairman and CEO of HDI. "We are poised for significant growth and this is the perfect time to bolster the sales and marketing team."
Hypertension Diagnostics, Inc. strives to save lives by reducing the risk of cardiovascular disease using the CVProfilor. The CVProfilor measures the elasticity of small and large arteries, a key indicator of cardiovascular health. More information is available at http://www.hdii.com/ .
Forward-looking statements in this press release are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company wishes to caution readers not to place undue reliance on any forward-looking statements and to recognize that the statements are not a prediction of actual future results. Actual results could differ materially from those presented and anticipated in the forward-looking statements due to the risks and uncertainties set forth in the Company's 2004 Annual Report on Form 10-KSB, and subsequent Quarterly Reports on Form 10-QSB, all of which were filed with the U.S. Securities and Exchange Commission, as well as others not now anticipated.
CVProfilor is a registered trademark of Hypertension Diagnostics, Inc. Hypertension Diagnostics, HDI/PulseWave, PulseWave and CVProfile are trademarks of Hypertension Diagnostics, Inc. All rights reserved. Website: http://www.hdii.com/
Hypertension Diagnostics Inc.CONTACT: Mark N. Schwartz, CEO of Hypertension Diagnostics Inc.,+1-651-687-9999
Web site: http://www.hdii.com/
